48 results
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
13 May 24
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
2:30pm
of Superkines, announced today that the American Society of Clinical Oncology ("ASCO") decided to reverse its decision and to withdraw Medicenna’s
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
25 Apr 24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
2:00pm
of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.
The oral podium presentation will include new
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
, University of Pennsylvania) at the 2023 Annual Meeting of the Society for Neuro-Oncology (“SNO”) held in Vancouver, Canada.
On November 6, 2023 … melanoma patients (> 20 to 80 weeks). This data was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) held
6-K
EX-99.5
MDNAF
Medicenna Therapeutics Corp.
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
). This data was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") held in San Diego.
On October 25, 2023 … summary at the Annual Meeting of the Society of Neuro-Oncology (SNO) highlighting longer term follow up results from the Phase 2b clinical trial
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
21 Nov 23
Current report (foreign)
10:39am
of the Society for NeuroOncology
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low … for Precision Surgery, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania) at the Society for Neuro-Oncology (SNO) 2023 Annual
6-K
EX-99.5
8n9urf2shedl1ncw
14 Nov 23
Interim condensed consolidated financial statements of
12:00am
6-K
EX-99.2
2jlhk
14 Nov 23
Interim condensed consolidated financial statements of
12:00am
6-K
EX-99.1
omtffypf74
25 Oct 23
Current report (foreign)
3:51pm
6-K
nll9jd3qi
25 Oct 23
Current report (foreign)
3:51pm
6-K
EX-99.1
u1g3ei rluyif3mqcs4
24 Oct 23
Current report (foreign)
7:18am
6-K
EX-99.5
utgmn
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
6-K
EX-99.2
flyh4madlg5bcofq1
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
6-K
EX-99.1
sgegonhhz dfdem
25 Jul 23
Medicenna Presents at National Brain Tumor Society's Research Round Table
8:00am
6-K
EX-99.1
fhe46cq3a
27 Jun 23
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
2:35pm
6-K
EX-99.1
cy7tr3 9dmc6r001e0
10 Nov 22
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting
9:05am
6-K
EX-99.5
s0vjcxqhsjbe2vwoltfd
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.2
pv4nrid0
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.1
g1d4t81 zmj4x8sm3a
5 Oct 22
Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
8:28am